Cancers that overexpress a specific receptor that simultaneously exists on healthy cells make an ideal target for similar strategies, such as CD20 for B-cell lymphoma or CD30 for Hodgkin’s lymphoma. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.